Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) specializes in developing abuse-deterrent medications for chronic pain and neuropsychiatric conditions through its proprietary DETERx® technology. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, product developments, and strategic initiatives shaping the company's trajectory in specialty pharmaceuticals.
Access comprehensive coverage of COLL's latest press releases, including advancements in pain management solutions like Xtampza ER® and Nucynta®, as well as its expansion into ADHD treatment with Jornay PM®. The page aggregates essential updates on financial performance, partnership announcements, and intellectual property developments critical for assessing the company's market position.
Bookmark this resource for structured access to Collegium's most significant announcements, from clinical trial results to manufacturing updates. Our curated news feed ensures you stay informed about COLL's efforts to address opioid misuse while delivering innovative therapeutic solutions across multiple medical disciplines.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
